Published in Clin Lung Cancer on March 01, 2006
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Expression of FAK and PTEN in bronchioloalveolar carcinoma and lung adenocarcinoma. Lung (2009) 1.53
Metabolic profiling identifies lung tumor responsiveness to erlotinib. Exp Mol Pathol (2009) 0.86
Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma. PLoS One (2013) 0.85
Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients. Clin Lung Cancer (2011) 0.84
Jaagsiekte sheep retrovirus detected in human lung cancer tissue arrays. BMC Res Notes (2014) 0.84
Cigarette smoking associated with lung adenocarcinoma in situ in a large case-control study (SFBALCS). J Thorac Oncol (2012) 0.83
Predictors of lung cancer: noteworthy cell type differences. Perm J (2013) 0.83
Lung cancer in never smokers. Semin Respir Crit Care Med (2011) 0.81
Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis. Radiat Oncol (2013) 0.78
Bronchioloalveolar carcinoma: the "changing face of lung cancer". Clin Lung Cancer (2006) 0.78
Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. J Cardiothorac Surg (2013) 0.77
Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA). Cancer Epidemiol Biomarkers Prev (2015) 0.75
Sclerosing variant of the bronchioloalveolar carcinoma: imaging findings in an atypical case. Case Rep Med (2010) 0.75
Characterization of a transgenic mouse model exhibiting spontaneous lung adenocarcinomas with a metastatic phenotype. PLoS One (2017) 0.75
Claudin-1 correlates with poor prognosis in lung adenocarcinoma. Thorac Cancer (2016) 0.75
Clinical importance of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in the management of patients with bronchoalveolar carcinoma: Role in the detection of recurrence. Oncol Lett (2013) 0.75
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst (2007) 4.07
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18
The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology (2002) 3.02
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res (2002) 2.96
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res (2005) 2.81
Natural history of stage I non-small cell lung cancer: implications for early detection. Chest (2007) 2.78
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol (2007) 2.35
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck (2008) 2.28
A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA (2012) 2.25
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun (2002) 2.09
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer. J Thorac Oncol (2011) 2.09
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09
Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene (2005) 2.06
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet (2004) 2.05
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res (2002) 1.96
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene (2003) 1.93
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest (2005) 1.89
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol (2010) 1.79
Wnt signaling in lung cancer. Cancer Lett (2005) 1.77
Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer (2010) 1.76
An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res (2007) 1.73
Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res (2003) 1.70
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys (2008) 1.68
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res (2004) 1.64
Function of the respiratory syncytial virus small hydrophobic protein. J Virol (2007) 1.64
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med (2009) 1.62
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res (2008) 1.62
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett (2003) 1.60
Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer. Clin Lung Cancer (2009) 1.60
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res (2014) 1.59
Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer (2005) 1.57
A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia (2004) 1.54
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics (2004) 1.53
Emergent surgery for massive pulmonary embolism on the basis of clinical diagnosis. Tex Heart Inst J (2003) 1.52
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene (2004) 1.52
c-Kit is not expressed in malignant mesothelioma. Mod Pathol (2003) 1.49
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg (2002) 1.49
Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol (2010) 1.49
A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol (2013) 1.47
The role of simian virus 5 V protein on viral RNA synthesis. Virology (2005) 1.46
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res (2008) 1.43
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One (2008) 1.43
Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. J Virol (2003) 1.40
Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential? Lung Cancer (2009) 1.39
Function of small hydrophobic proteins of paramyxovirus. J Virol (2006) 1.39
Clinical patterns of metastasis. Cancer Metastasis Rev (2006) 1.32
Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun (2004) 1.31
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev (2014) 1.31
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol (2008) 1.30
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res (2005) 1.27
A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A (2009) 1.27
Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses. J Virol (2007) 1.27
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst (2011) 1.27
The role of the clinical research coordinator--data manager--in oncology clinical trials. BMC Med Res Methodol (2004) 1.26
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer (2009) 1.24
ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer (2012) 1.22
Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer (2009) 1.22
Update on the molecular biology of malignant mesothelioma. Cancer (2007) 1.22
Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res (2004) 1.22
KRAS mutations in lung cancer. Clin Lung Cancer (2012) 1.22
Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med (2011) 1.21
Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene (2005) 1.20
Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles. J Virol (2009) 1.17